Oncologic Application For Opdivo (Nivolumab)

OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of: • patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. • patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. • patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. • patients with metastatic small cell lung cancer with progression after platinum-based chemotherapy and at least one other line of therapy. • patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. • patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma, in combination with ipilimumab. patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. • patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. • patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as a single agent or in combination with ipilimumab. • patients with hepatocellular carcinoma who have been previously treated with sorafenib, as a single agent or in combination with ipilimumab. <a id="